Innovating medication reviews through a technology-enabled process
Copyright © 2021 Elsevier Inc. All rights reserved..
Medication reviews are effective in improving the quality of medication use among older people. However, they are conducted to various standards resulting in a wide range of outcomes which limit generalisability of findings arising from research studies. There also appear to be funding and time constraints, lack of data storage for quality improvement purposes, and non-standardised reporting of outcomes, especially clinically relevant outcomes. Furthermore, the coronavirus disease-19 (COVID-19) pandemic has restricted many face-to-face activities, including medication reviews. This article introduces a technology-enabled approach to medication reviews that may overcome some limitations with current medication review processes, and also make it possible to conduct medication reviews during the COVID-19 pandemic by providing an alternate platform. The possible advantages of this technology-enabled approach, legislative considerations and possible implementation in practice are discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Research in social & administrative pharmacy : RSAP - 18(2022), 4 vom: 16. Apr., Seite 2700-2705 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thiruchelvam, Kaeshaelya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Computerised decision support system |
|---|
| Anmerkungen: |
Date Completed 24.02.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.sapharm.2021.07.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328706051 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328706051 | ||
| 003 | DE-627 | ||
| 005 | 20231225203517.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.sapharm.2021.07.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328706051 | ||
| 035 | |a (NLM)34326004 | ||
| 035 | |a (PII)S1551-7411(21)00277-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thiruchelvam, Kaeshaelya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Innovating medication reviews through a technology-enabled process |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a Medication reviews are effective in improving the quality of medication use among older people. However, they are conducted to various standards resulting in a wide range of outcomes which limit generalisability of findings arising from research studies. There also appear to be funding and time constraints, lack of data storage for quality improvement purposes, and non-standardised reporting of outcomes, especially clinically relevant outcomes. Furthermore, the coronavirus disease-19 (COVID-19) pandemic has restricted many face-to-face activities, including medication reviews. This article introduces a technology-enabled approach to medication reviews that may overcome some limitations with current medication review processes, and also make it possible to conduct medication reviews during the COVID-19 pandemic by providing an alternate platform. The possible advantages of this technology-enabled approach, legislative considerations and possible implementation in practice are discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Computerised decision support system | |
| 650 | 4 | |a Innovation | |
| 650 | 4 | |a Medication reviews | |
| 650 | 4 | |a Technology | |
| 700 | 1 | |a Byles, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Syed Shahzad |e verfasserin |4 aut | |
| 700 | 1 | |a Kairuz, Therese |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Research in social & administrative pharmacy : RSAP |d 2005 |g 18(2022), 4 vom: 16. Apr., Seite 2700-2705 |w (DE-627)NLM166902047 |x 1934-8150 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:4 |g day:16 |g month:04 |g pages:2700-2705 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.sapharm.2021.07.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 4 |b 16 |c 04 |h 2700-2705 | ||